Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: Role of erythropoietin on progenitor cell mobilization

Journal of Physiology

Volumn 586, Issue 23, 2008, Pages 5757-5769

  Lin, Jih Shyong ^a   Chen, Yih Sharng ^b   Chiang, Han Sun ^c   Ma, Ming Chieh ^c  

^a TAO YUAN GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN RECEPTOR; NEUTRALIZING ANTIBODY; OXYGEN; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

AMBIENT AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CELL COUNT; CELL HOMING; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY LIGATION; DISEASE SEVERITY; FEMALE; HEART INFARCTION PREVENTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEMATOCRIT; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; LEFT CORONARY ARTERY; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; RISK REDUCTION; STEM CELL MOBILIZATION; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CELL MOTILITY; ENZYME ACTIVATION; HEART PROTECTION; HYPOXIC PRECONDITIONING; IN VITRO STUDY; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STEM CELL;

ANIMALS; ANOXIA; ANTIBODIES; ANTIGENS, CD34; CHEMOKINE CXCL12; CREATINE KINASE, MB FORM; ERYTHROPOIETIN; GENE EXPRESSION; HEART; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MODELS, BIOLOGICAL; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; RECEPTORS, CXCR4; RECEPTORS, ERYTHROPOIETIN; REPERFUSION INJURY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR FUNCTION, LEFT;

EID: 57049120087     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2008.160887     Document Type: Article

References (50)

1. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS & Giordano FJ (2004). Stromal cell-derived factor-1α plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110, 3300-3305.
2. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ & Penn MS (2003). Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362, 697-703.
3. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL & Robbins RC (2004). Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428, 668-673.
4. Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wiesener MS & Eckardt KU (2007). Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol 435, 221-245.
5. Burger JA & Kipps TJ (2006). CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761-1767.
6. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL & Semenza GL (2003). Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108, 79-85.
7. Chan CY, Chen YS, Lee HH, Huang HS, Lai YL, Chen CF & Ma MC (2007). Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: Role of Jak2-ERK pathway. Life Sci 81, 717-723.
8. Chen YS, Chien CT, Ma MC, Tseng YZ, Lin FY, Wang SS & Chen CF (2005). Protection 'outside the box' (skeletal remote preconditioning) in rat model is triggered by free radical pathway. J Surg Res 126, 92-101.
9. Clanton TL & Klawitter PF (2001). Adaptive responses of skeletal muscle to intermittent hypoxia: The known and the unknown. J Appl Physiol 90, 2476-2487.
10. Das DK & Maulik N (2006). Cardiac genomic response following preconditioning stimulus. Cardiovasc Res 70, 254-263.
11. Dong JW, Zhu HF, Zhu WZ, Ding HL, Ma TM & Zhou ZN (2003). Intermittent hypoxia attenuates ischemia/reperfusion induced apoptosis in cardiac myocytes via regulating Bcl-2/Bax expression. Cell Res 13, 385-391.
12. Fandrey J (2004). Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 286, R977-R988.
13. Feng NH, Lee HH, Shiang JC & Ma MC (2008). Transient receptor potential vanilloid type 1 channels act as mechanoreceptors and cause substance P release and sensory activation in rat kidneys. Am J Physiol Renal Physiol 294, F316-F325.
14. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R & Keshet E (2006). VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 124, 175-189.
15. Hamed S, Barshack I, Luboshits G, Wexler D, Deutsch V, Keren G & George J (2006). Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 27, 1876-1883.
16. Ishikawa Y & Ito T (1988). Kinetics of hemopoietic stem cells in a hypoxic culture. Eur J Haematol 40, 126-129.
17. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK & Goodell MA (2001). Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 107, 1395-1402.
18. + hemangiocytes. Nat Med 12, 557-567.
19. Jones SS, D'Andrea AD, Haines LL & Wong GG (1990). Human erythropoietin receptor: Cloning, expression, and biologic characterization. Blood 76, 31-35.
20. Kolár F, JezkováJ, BalkováP, Breh J, Neckár J, Novák F, NovákováO, TomásováH, SrbováM, Ost'ádal B, Wilhelm J & Herget J (2007). Role of oxidative stress in PKC-δ upregulation and cardioprotection induced by chronic intermittent hypoxia. Am J Physiol Heart Circ Physiol 292, H224-H230.
21. Kolár F & Ost'ádal B (2004). Molecular mechanisms of cardiac protection by adaptation to chronic hypoxia. Physiol Res 53, S3-S13.
22. Kucia M, Ratajczak J & Ratajczak MZ (2005a). Bone marrow as a source of circulating CXCR4+ tissue-committed stem cells. Biol Cell 97, 133-146.
23. Kucia M, Reca R, Jala VR, Dawn B, Ratajczak J & Ratajczak MZ (2005b). Bone marrow as a home of heterogenous populations of nonhematopoietic stem cells. Leukemia 19, 1118-1127.
24. Kumar R, Stepanek F & Mantalaris A (2004). An oxygen transport model for human bone marrow microcirculation. Food Bioproducts Process 82, 105-116.
25. Lachmanova V, Hnilickova O, Povysilova V, Hampl V & Herget J (2005). N-acetylcysteine inhibits hypoxic pulmonary hypertension most effectively in the initial phase of chronic hypoxia. Life Sci 77, 175-182.
26. Ma MC, Qian H, Ghassemi F, Zhao P & Xia Y (2005). Oxygen sensitive δ-opioid receptor-regulated survival and death signals: Novel insights into neuronal preconditioning and protection. J Biol Chem 280, 16208-16218.
27. Maiese K, Li F & Chong ZZ (2005). New avenues of exploration for erythropoietin. JAMA 293, 90-95.
28. Maloyan A, Eli-Berchoer L, Semenza GL, Gerstenblith G, Stern MD & Horowitz M (2005). HIF-1α-targeted pathways are activated by heat acclimation and contribute to acclimation-ischemic cross-tolerance in the heart. Physiol Genomics 23, 79-88.
29. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I & Overall CM (2001). Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 276, 43503-43508.
30. Milano G, Corno AF, Lippa S, Von Segesser LK & Samaja M (2002). Chronic and intermittent hypoxia induce different degrees of myocardial tolerance to hypoxia-induced dysfunction. Exp Biol Med (Maywood) 227, 389-397.
31. Murry CE, Jennings RB & Reimer KA (1986). Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74, 1124-1136.
32. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA & Field LJ (2004). Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428, 664-668.
33. National Research Council (1996). Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
34. Neubauer JA (2001). Physiological and pathophysiological responses to intermittent hypoxia. J Appl Physiol 90, 1593-1599.
35. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS & Koch WJ (2003). A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112, 999-1007.
36. Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, Raffestin B & Frelin C (1998). Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 275, H1948-H1956.
37. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D & Lapidot T (2002). G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3, 687-694.
38. Prabhakar NR (2001). Oxygen sensing during intermittent hypoxia: cellular and molecular mechanisms. J Appl Physiol 90, 1986-1994.
39. Salcedo R, Zhang X, Young HA, Michael N, Wasserman K, Ma WH, Martins-Green M, Murphy WJ & Oppenheim JJ (2003). Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102, 1966-1977.
40. Saxena A, Fish JE, White MD, Yu S, Smyth JW, Shaw RM, DiMaio JM & Srivastava D (2008). Stromal cell-derived factor-1α is cardioprotective after myocardial infarction. Circulation 117, 2224-2231.
41. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L, Mantovani A, Melillo G & Sica A (2003). Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198, 1391-1402.
42. Segret A, Rücker-Martin C, Pavoine C, Flavigny J, Deroubaix E, Châtel MA, Lombet A & Renaud JF (2007). Structural localization and expression of CXCL12 and CXCR4 in rat heart and isolated cardiac myocytes. J Histochem Cytochem 55, 141-150.
43. Semenza GL (2000). HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88, 1474-1480.
44. Shi M, Li J, Liao L, Chen B, Li B, Chen L, Jia H & Zhao RC (2007). Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: Role in homing efficiency in NOD/SCID mice. Haematologica 92, 897-904.
45. Tang YL, Qian K, Zhang YC, Shen L & Phillips MI (2005). Mobilizing of haematopoietic stem cells to ischemic myocardium by plasmid mediated stromal-cell-derived factor-1α (SDF-1α) treatment. Regul Pept 125, 1-8.
46. Vandervelde S, van Luyn MJ, Tio RA & Harmsen MC (2005). Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol 39, 363-376.
47. Westenbrink BD, Lipsic E, Van Der Meer P, Van Der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH & Schoemaker RG (2007). Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28, 2018-2027.
48. Wu H, Lee SH, Gao J, Liu X & Iruela-Arispe ML (1999). Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126, 3597-3605.
49. 2+ exchange and ryanodine receptor activities in ischemia-reperfusion. Am J Physiol Cell Physiol 292, C2046-C2056.
50. Zhu WZ, Xie Y, Chen L, Yang HT & Zhou ZN (2006). Intermittent high altitude hypoxia inhibits opening of mitochondrial permeability transition pores against reperfusion injury. J Mol Cell Cardiol 40, 96-106.